General Updates

Date: October 08, 2026 Ref. No.: KDL/SE/053/2026-27 To, To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, Plot No. C-1, Block G, 25th Floor, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (East) Dalal Street, Mumbai- 400001. Mumbai – 400051 Scrip Code: 543328 NSE Symbol: KRSNAA Dear Sir/Madam, Sub: Intimation of receipt of In-principle Approval received from BSE Limited and National Stock Exchange of India Limited for issue of 16,21,000 convertible warrants on Preferential basis in terms of Regulation 28(1) to the Promoter and Promoter Group of the Company Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 "SEBI (LODR)", we wish to inform you that the Company has received In-principle Approval from BSE Limited and National Stock Exchange of India Limited ('the Exchanges') vide letters nos. LOD/PREF/PB/FIP/908/2026- 27 and NSE/LIST/56990 respectively, for issue of 16,21,000 warrants convertible into 16,21,000 Equity shares of face value Rs. 5/- each at an issue price of Rs. 566/- each to the Promoter and Promoter Group of the Company on preferential basis in terms of Regulation 28(1). A copy of the in-principle approval letter received from NSE is enclosed herewith. The in- principle approval letter received from BSE contains certain factual errors that require rectification. Accordingly, the corrected letter will be intimated to the Exchanges separately upon its receipt. The above information will also be available on the website of the Company at https://krsnaadiagnostics.com/investors/. You are requested to take the above information on record. Thanking you, Yours sincerely For Krsnaa Diagnostics Limited Sujoy Sudipta Bose Company Secretary & Compliance Officer Encl: as above